<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mounting evidence exists that alterations of ubiquitination processes are involved in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> pathogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>Speckle-type POZ protein (SPOP) is a key adaptor for Cul3-based ubiquitination process </plain></SENT>
<SENT sid="2" pm="."><plain>Recent studies reported that SPOP may be a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene (TSG) and <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> of SPOP was detected in <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> (<z:chebi fb="20" ids="36751">PCA</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this study was to see whether alterations of SPOP protein expression and <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> of SPOP gene are features of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we analyzed SPOP <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> in 45 gastric (GC), 45 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and 45 PCA by single-strand conformation polymorphism (SSCP) </plain></SENT>
<SENT sid="5" pm="."><plain>Also, we analyzed SPOP protein expression in 60 GC, 60 CRC and 60 PCA by immunohistochemistry </plain></SENT>
<SENT sid="6" pm="."><plain>Overall, we detected three somatic missense mutations of SPOP gene in the coding sequences (p.Ser14Leu, p.Tyr87Cys and p.Phe133Leu) </plain></SENT>
<SENT sid="7" pm="."><plain>The mutations were observed in two <z:chebi fb="20" ids="36751">PCA</z:chebi> and one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Of note, the p.Phe133Leu was a recurrent mutation reported in an earlier study </plain></SENT>
<SENT sid="9" pm="."><plain>In the immunohistochemistry, SPOP protein was expressed in <z:mpath ids='MPATH_458'>normal</z:mpath> gastric, colonic and prostate epithelial cells, whereas it was lost in 30% of GC, 20% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and 37% of <z:chebi fb="20" ids="36751">PCA</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Our data indicate that loss of SPOP expression was common in GC, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:chebi fb="20" ids="36751">PCA</z:chebi>, but <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> of SPOP in this study was rare in these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Also, the data provide a possibility that loss of expression of SPOP gene might play a role in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> pathogenesis by altering TSG functions of SPOP </plain></SENT>
</text></document>